Annual EBITDA:
-$178.85M+$79.39M(+30.74%)Summary
- As of today, ALNY annual EBITDA is -$178.85 million, with the most recent change of +$79.39 million (+30.74%) on December 31, 2024.
- During the last 3 years, ALNY annual EBITDA has risen by +$440.58 million (+71.13%).
- ALNY annual EBITDA is now -4172.50% below its all-time high of -$4.19 million, reached on December 31, 2002.
Performance
ALNY EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Quarterly EBITDA:
$381.79M+$384.04M(+17030.60%)Summary
- As of today, ALNY quarterly EBITDA is $381.79 million, with the most recent change of +$384.04 million (+17030.60%) on September 30, 2025.
- Over the past year, ALNY quarterly EBITDA has increased by +$444.71 million (+706.75%).
- ALNY quarterly EBITDA is now at all-time high.
Performance
ALNY Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
TTM EBITDA:
$321.02M+$444.71M(+359.54%)Summary
- As of today, ALNY TTM EBITDA is $321.02 million, with the most recent change of +$444.71 million (+359.54%) on September 30, 2025.
- Over the past year, ALNY TTM EBITDA has increased by +$453.17 million (+342.93%).
- ALNY TTM EBITDA is now at all-time high.
Performance
ALNY TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
ALNY EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1Y1 Year | +30.7% | +706.8% | +342.9% |
| 3Y3 Years | +71.1% | +254.3% | +142.8% |
| 5Y5 Years | +78.5% | +276.2% | +135.6% |
ALNY EBITDA Highs & Lows
| PeriodPeriod | Annual vs HighAnnual vs High | Annual vs LowAnnual vs Low | Quarter. vs HighQuarter. vs High | Quarter. vs LowQuarter. vs Low | TTM vs HighTTM vs High | TTM vs LowTTM vs Low | |
|---|---|---|---|---|---|---|---|
| 3Y | 3-Year | at high | +80.7% | at high | +254.3% | at high | +141.5% |
| 5Y | 5-Year | at high | +80.7% | at high | +254.3% | at high | +135.6% |
| All-Time | All-Time | -4172.5% | +80.7% | at high | +230.5% | at high | +133.9% |
ALNY EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2025 | - | $381.79M(>+9900.0%) | $321.02M(+359.5%) |
| Jun 2025 | - | -$2.25M(-106.9%) | -$123.69M(-113.9%) |
| Mar 2025 | - | $32.48M(+135.7%) | -$57.81M(+51.9%) |
| Dec 2024 | -$178.85M(+30.7%) | -$90.99M(-44.6%) | -$120.22M(+9.0%) |
| Sep 2024 | - | -$62.92M(-198.9%) | -$132.15M(-183.7%) |
| Jun 2024 | - | $63.62M(+312.6%) | $157.97M(+229.2%) |
| Mar 2024 | - | -$29.92M(+70.9%) | -$122.30M(+46.4%) |
| Dec 2023 | -$258.24M(+72.1%) | -$102.92M(-145.3%) | -$228.12M(+23.8%) |
| Sep 2023 | - | $227.19M(+204.9%) | -$299.50M(+61.3%) |
| Jun 2023 | - | -$216.65M(-59.6%) | -$774.14M(-4.7%) |
| Mar 2023 | - | -$135.74M(+22.1%) | -$739.07M(+0.2%) |
| Dec 2022 | -$926.56M(-49.6%) | -$174.30M(+29.6%) | -$740.60M(+1.2%) |
| Sep 2022 | - | -$247.44M(-36.3%) | -$749.49M(-11.5%) |
| Jun 2022 | - | -$181.59M(-32.3%) | -$671.94M(-7.6%) |
| Mar 2022 | - | -$137.27M(+25.1%) | -$624.70M(+5.5%) |
| Dec 2021 | -$619.43M(+11.1%) | -$183.19M(-7.8%) | -$661.09M(+0.1%) |
| Sep 2021 | - | -$169.89M(-26.4%) | -$661.74M(+6.6%) |
| Jun 2021 | - | -$134.35M(+22.6%) | -$708.47M(+7.4%) |
| Mar 2021 | - | -$173.65M(+5.5%) | -$764.77M(+3.6%) |
| Dec 2020 | -$696.67M(+16.2%) | -$183.84M(+15.1%) | -$793.67M(+12.1%) |
| Sep 2020 | - | -$216.63M(-13.6%) | -$902.46M(+1.1%) |
| Jun 2020 | - | -$190.66M(+5.9%) | -$912.36M(+3.8%) |
| Mar 2020 | - | -$202.54M(+30.8%) | -$948.22M(-2.8%) |
| Dec 2019 | -$830.88M(-11.5%) | -$292.63M(-29.2%) | -$922.26M(-8.2%) |
| Sep 2019 | - | -$226.52M(+0.0%) | -$852.21M(+2.8%) |
| Jun 2019 | - | -$226.53M(-28.3%) | -$877.00M(-4.3%) |
| Mar 2019 | - | -$176.58M(+20.7%) | -$840.59M(-4.0%) |
| Dec 2018 | -$745.43M(-52.7%) | -$222.58M(+11.4%) | -$808.24M(-10.8%) |
| Sep 2018 | - | -$251.31M(-32.2%) | -$729.24M(-21.5%) |
| Jun 2018 | - | -$190.12M(-31.8%) | -$600.14M(-13.8%) |
| Mar 2018 | - | -$144.23M(-0.4%) | -$527.44M(-8.4%) |
| Dec 2017 | -$488.19M(-19.2%) | -$143.59M(-17.5%) | -$486.72M(-6.8%) |
| Sep 2017 | - | -$122.21M(-4.1%) | -$455.55M(-4.4%) |
| Jun 2017 | - | -$117.41M(-13.4%) | -$436.51M(-7.1%) |
| Mar 2017 | - | -$103.51M(+7.9%) | -$407.54M(+0.5%) |
| Dec 2016 | -$409.46M(-47.8%) | -$112.42M(-9.0%) | -$409.46M(-6.5%) |
| Sep 2016 | - | -$103.18M(-16.7%) | -$384.49M(-8.5%) |
| Jun 2016 | - | -$88.44M(+16.1%) | -$354.37M(-6.1%) |
| Mar 2016 | - | -$105.43M(-20.6%) | -$333.85M(-20.5%) |
| Dec 2015 | -$276.96M(-60.8%) | -$87.44M(-19.7%) | -$276.96M(-19.4%) |
| Sep 2015 | - | -$73.06M(-7.6%) | -$231.89M(-15.4%) |
| Jun 2015 | - | -$67.92M(-40.0%) | -$200.91M(-12.2%) |
| Mar 2015 | - | -$48.53M(-14.5%) | -$179.01M(-3.9%) |
| Dec 2014 | -$172.29M | -$42.37M(-0.7%) | -$172.29M(-9.8%) |
| Sep 2014 | - | -$42.08M(+8.6%) | -$156.88M(-8.7%) |
| Jun 2014 | - | -$46.03M(-10.1%) | -$144.27M(-23.5%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2014 | - | -$41.81M(-55.0%) | -$116.84M(-41.3%) |
| Dec 2013 | -$82.71M(-51.7%) | -$26.96M(+8.5%) | -$82.71M(-7.3%) |
| Sep 2013 | - | -$29.47M(-58.4%) | -$77.08M(-21.4%) |
| Jun 2013 | - | -$18.60M(-142.3%) | -$63.47M(-16.8%) |
| Mar 2013 | - | -$7.68M(+64.0%) | -$54.33M(+2.0%) |
| Dec 2012 | -$54.53M(-9.7%) | -$21.33M(-34.5%) | -$55.42M(-19.3%) |
| Sep 2012 | - | -$15.86M(-67.6%) | -$46.45M(-11.2%) |
| Jun 2012 | - | -$9.46M(-7.9%) | -$41.76M(+5.4%) |
| Mar 2012 | - | -$8.77M(+29.0%) | -$44.13M(+11.2%) |
| Dec 2011 | -$49.69M(-28.1%) | -$12.35M(-10.5%) | -$49.69M(-2.5%) |
| Sep 2011 | - | -$11.18M(+5.5%) | -$48.46M(-8.3%) |
| Jun 2011 | - | -$11.83M(+17.5%) | -$44.75M(-3.3%) |
| Mar 2011 | - | -$14.34M(-28.9%) | -$43.32M(-10.7%) |
| Dec 2010 | -$38.80M(+5.4%) | -$11.12M(-49.0%) | -$39.13M(-12.0%) |
| Sep 2010 | - | -$7.46M(+28.3%) | -$34.94M(+3.0%) |
| Jun 2010 | - | -$10.40M(-2.5%) | -$36.02M(+21.8%) |
| Mar 2010 | - | -$10.14M(-46.3%) | -$46.09M(-9.4%) |
| Dec 2009 | -$41.02M(-116.6%) | -$6.93M(+18.8%) | -$42.12M(-2.2%) |
| Sep 2009 | - | -$8.54M(+58.3%) | -$41.20M(-20.2%) |
| Jun 2009 | - | -$20.47M(-231.3%) | -$34.27M(-35.5%) |
| Mar 2009 | - | -$6.18M(-2.7%) | -$25.28M(-14.3%) |
| Dec 2008 | -$18.93M(+74.8%) | -$6.01M(-275.2%) | -$22.11M(-22.3%) |
| Sep 2008 | - | -$1.60M(+86.0%) | -$18.08M(+71.3%) |
| Jun 2008 | - | -$11.48M(-282.1%) | -$62.97M(+3.9%) |
| Mar 2008 | - | -$3.01M(-51.1%) | -$65.50M(+23.2%) |
| Dec 2007 | -$75.06M(-110.3%) | -$1.99M(+95.7%) | -$85.30M(+7.5%) |
| Sep 2007 | - | -$46.49M(-231.7%) | -$92.21M(-72.9%) |
| Jun 2007 | - | -$14.02M(+38.5%) | -$53.33M(-7.8%) |
| Mar 2007 | - | -$22.80M(-156.1%) | -$49.48M(-38.6%) |
| Dec 2006 | -$35.69M(+11.6%) | -$8.90M(-17.0%) | -$35.69M(+12.8%) |
| Sep 2006 | - | -$7.61M(+25.1%) | -$40.95M(+5.4%) |
| Jun 2006 | - | -$10.16M(-12.8%) | -$43.27M(+0.2%) |
| Mar 2006 | - | -$9.01M(+36.4%) | -$43.35M(-7.4%) |
| Dec 2005 | -$40.35M(-35.3%) | -$14.16M(-42.6%) | -$40.35M(-30.3%) |
| Sep 2005 | - | -$9.93M(+3.1%) | -$30.97M(-15.8%) |
| Jun 2005 | - | -$10.25M(-70.7%) | -$26.74M(-16.2%) |
| Mar 2005 | - | -$6.01M(-25.6%) | -$23.00M(+22.9%) |
| Dec 2004 | -$29.82M(-52.1%) | -$4.78M(+16.1%) | -$29.82M(+34.6%) |
| Sep 2004 | - | -$5.70M(+12.6%) | -$45.62M(-14.4%) |
| Jun 2004 | - | -$6.52M(+49.1%) | -$39.88M(-13.5%) |
| Mar 2004 | - | -$12.82M(+37.7%) | -$35.14M(-49.0%) |
| Dec 2003 | -$19.61M(-368.5%) | -$20.58M(>-9900.0%) | -$23.59M(-684.6%) |
| Sep 2003 | - | $44.00K(+102.5%) | -$3.01M(+1.4%) |
| Jun 2003 | - | -$1.78M(-40.9%) | -$3.05M(-140.9%) |
| Mar 2003 | - | -$1.27M | -$1.27M |
| Dec 2002 | -$4.19M | - | - |
FAQ
- What is Alnylam Pharmaceuticals, Inc. annual EBITDA?
- What is the all-time high annual EBITDA for Alnylam Pharmaceuticals, Inc.?
- What is Alnylam Pharmaceuticals, Inc. annual EBITDA year-on-year change?
- What is Alnylam Pharmaceuticals, Inc. quarterly EBITDA?
- What is the all-time high quarterly EBITDA for Alnylam Pharmaceuticals, Inc.?
- What is Alnylam Pharmaceuticals, Inc. quarterly EBITDA year-on-year change?
- What is Alnylam Pharmaceuticals, Inc. TTM EBITDA?
- What is the all-time high TTM EBITDA for Alnylam Pharmaceuticals, Inc.?
- What is Alnylam Pharmaceuticals, Inc. TTM EBITDA year-on-year change?
What is Alnylam Pharmaceuticals, Inc. annual EBITDA?
The current annual EBITDA of ALNY is -$178.85M
What is the all-time high annual EBITDA for Alnylam Pharmaceuticals, Inc.?
Alnylam Pharmaceuticals, Inc. all-time high annual EBITDA is -$4.19M
What is Alnylam Pharmaceuticals, Inc. annual EBITDA year-on-year change?
Over the past year, ALNY annual EBITDA has changed by +$79.39M (+30.74%)
What is Alnylam Pharmaceuticals, Inc. quarterly EBITDA?
The current quarterly EBITDA of ALNY is $381.79M
What is the all-time high quarterly EBITDA for Alnylam Pharmaceuticals, Inc.?
Alnylam Pharmaceuticals, Inc. all-time high quarterly EBITDA is $381.79M
What is Alnylam Pharmaceuticals, Inc. quarterly EBITDA year-on-year change?
Over the past year, ALNY quarterly EBITDA has changed by +$444.71M (+706.75%)
What is Alnylam Pharmaceuticals, Inc. TTM EBITDA?
The current TTM EBITDA of ALNY is $321.02M
What is the all-time high TTM EBITDA for Alnylam Pharmaceuticals, Inc.?
Alnylam Pharmaceuticals, Inc. all-time high TTM EBITDA is $321.02M
What is Alnylam Pharmaceuticals, Inc. TTM EBITDA year-on-year change?
Over the past year, ALNY TTM EBITDA has changed by +$453.17M (+342.93%)